- ►prsjournal.com AE Fung, RB Bhisitkul - British Journal of Ophthalmology, 2008 - bjo.bmj.com Ocular anti-vascular endothelial growth factor (VEGF) therapy has brought
dramatic benefits to patients with exudative age-related macular degeneration
(AMD), and promises near-term advances in other major diseases such as ... Related articles - All 5 versions
PC Issa, FG Holz, HPN Scholl, G Bonn - Ophthalmology, 2007 - duanessolution.com 1. In 1968, Gass published a series of landmark articles describing fluorescein
angiography stud- ies of macular dysfunction secondary to retinal vascular
disease. One of these articles is referred to several times in the ... Related articles - View as HTML
G Querques, O Riuniti, I Foggia - Retina, 2009 - duanessolution.com 1. In 1968, Gass published a series of landmark articles describing fluorescein
angiography stud- ies of macular dysfunction secondary to retinal vascular
disease. One of these articles is referred to several times in the ... Related articles - View as HTML
- ►nih.gov LJ Singerman, H Masonson, M Patel, AP … - British Medical Journal, 2008 - bjo.bmj.com Methods: Two concurrent, prospective, multicentre, double-masked studies
randomised subjects with all angiographic lesion compositions of NV-AMD to
receive intravitreous pegaptanib sodium (0.3, 1 and 3 mg) or sham ... Cited by 4 - Related articles - All 9 versions
- ►prsjournal.com S Bopp - British Journal of Ophthalmology, 2007 - bjo.bmj.com In the era of anti-vascular endothelial growth factor (VEGF) therapy for
exudative age-related macular degeneration (ARMD), a paradigm shift has emerged.
Until then, photodynamic therapy (PDT) was considered a successful ... Cited by 3 - Related articles - BL Direct - All 5 versions
S El-Beik, R Elliott - pharmj.com Age-related macular degeneration (AMD) is a degenerative disease and is one of
the leading causes of sight loss in the UK. There are approximately 26,000 new
cases of AMD diagnosed in the UK each year.1 About 10 per cent of people ... Related articles - All 2 versions
TY Wong, G Liew, P Mitchell - The Lancet, 2007 - Elsevier Whilst these new treatments are appropriately seen as important breakthroughs in
AMD management, the long-term systemic safety of intravitreal anti-VEGF drugs
remains unclear. Several concerns have not yet been addressed. First, ... Cited by 23 - Related articles - All 11 versions
JI Lim - jhasio.com Over the past decade, treatment of neovascular age-related macular degeneration
has evolved from overall retinal ablation to more targeted and retinal-sparing
therapy, beginning with the advent of photodynamic therapy and continuing ... Related articles
- ►duanessolution.com [PDF] PC Issa, FG Holz, HPN Scholl, G Bonn - Retina, 2009 - duanessolution.com 1. In 1968, Gass published a series of landmark articles describing fluorescein
angiography stud- ies of macular dysfunction secondary to retinal vascular
disease. One of these articles is referred to several times in the ... Related articles - View as HTML
